Effect of Vitamin D3 Supplementation on Upper Respiratory Tract Infections in Healthy Adults: The VIDARIS Randomized Controlled Trial | Infectious Diseases | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
Khoo AL, Chai L, Koenen H, Joosten I, Netea M, van der Ven A. Translating the role of vitamin D3 in infectious diseases.  Crit Rev Microbiol. 2012;38(2):122-13522304022PubMedGoogle ScholarCrossref
2.
Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey.  Arch Intern Med. 2009;169(4):384-39019237723PubMedGoogle ScholarCrossref
3.
Karatekin G, Kaya A, Salihoğlu Ö, Balci H, Nuhoğlu A. Association of subclinical vitamin D deficiency in newborns with acute lower respiratory infection and their mothers.  Eur J Clin Nutr. 2009;63(4):473-47718030309PubMedGoogle ScholarCrossref
4.
Laaksi I, Ruohola J-P, Tuohimaa P,  et al.  An association of serum vitamin D concentrations <40 nmol/L with acute respiratory tract infection in young Finnish men.  Am J Clin Nutr. 2007;86(3):714-71717823437PubMedGoogle Scholar
5.
Sattar N, Welsh P, Panarelli M, Forouhi NG. Increasing requests for vitamin D measurement: costly, confusing, and without credibility.  Lancet. 2012;379(9811):95-9622243814PubMedGoogle ScholarCrossref
6.
Avenell A, Cook JA, Maclennan GS, Macpherson GC. Vitamin D supplementation to prevent infections: a sub-study of a randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438).  Age Ageing. 2007;36(5):574-57717702768PubMedGoogle ScholarCrossref
7.
Laaksi I, Ruohola J-P, Mattila V, Auvinen A, Ylikomi T, Pihlajamäki H. Vitamin D supplementation for the prevention of acute respiratory tract infection: a randomized, double-blinded trial among young Finnish men.  J Infect Dis. 2010;202(5):809-81420632889PubMedGoogle ScholarCrossref
8.
Li-Ng M, Aloia JF, Pollack S,  et al.  A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections.  Epidemiol Infect. 2009;137(10):1396-140419296870PubMedGoogle ScholarCrossref
9.
Ilahi M, Armas LAG, Heaney RP. Pharmacokinetics of a single, large dose of cholecalciferol.  Am J Clin Nutr. 2008;87(3):688-69118326608PubMedGoogle Scholar
10.
Vieth R, Chan P-CR, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level.  Am J Clin Nutr. 2001;73(2):288-29411157326PubMedGoogle Scholar
11.
Barrett B, Hayney MS, Muller D,  et al.  Meditation or exercise for preventing acute respiratory infection: a randomized controlled trial.  Ann Fam Med. 2012;10(4):337-34622778122PubMedGoogle ScholarCrossref
12.
Barrett B, Brown R, Mundt M. Comparison of anchor-based and distributional approaches in estimating important difference in common cold.  Qual Life Res. 2008;17(1):75-8518027107PubMedGoogle ScholarCrossref
13.
Barrett B, Brown R, Mundt M,  et al.  The Wisconsin Upper Respiratory Symptom Survey is responsive, reliable, and valid.  J Clin Epidemiol. 2005;58(6):609-61715878475PubMedGoogle ScholarCrossref
14.
Barrett B, Locken K, Maberry R,  et al.  The Wisconsin Upper Respiratory Symptom Survey (WURSS): a new research instrument for assessing the common cold.  J Fam Pract. 2002;51(3):26511978238PubMedGoogle Scholar
15.
Barrett B, Brown RL, Mundt MP,  et al.  Validation of a short form Wisconsin Upper Respiratory Symptom Survey (WURSS-21).  Health Qual Life Outcomes. 2009;7:7619674476PubMedGoogle ScholarCrossref
16.
Jennings LC, MacDiarmid RD, Miles JAR. A study of acute respiratory disease in the community of Port Chalmers, I: illnesses within a group of selected families and the relative incidence of respiratory pathogens in the whole community.  J Hyg (Lond). 1978;81(1):49-66357651PubMedGoogle ScholarCrossref
17.
Monto AS, Sullivan KM. Acute respiratory illness in the community: frequency of illness and the agents involved.  Epidemiol Infect. 1993;110(1):145-1608432318PubMedGoogle ScholarCrossref
18.
Schafer JL. Analysis of Incomplete Multivariate Data. New York, NY: Chapman & Hall; 1997
19.
Camargo CA Jr, Ganmaa D, Frazier AL,  et al.  Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia.  Pediatrics. 2012;130(3):e561-e56722908115PubMedGoogle ScholarCrossref
20.
Manaseki-Holland S, Maroof Z, Bruce J,  et al.  Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial.  Lancet. 2012;379(9824):1419-142722494826PubMedGoogle ScholarCrossref
21.
Lehouck A, Mathieu C, Carremans C,  et al.  High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial.  Ann Intern Med. 2012;156(2):105-11422250141PubMedGoogle ScholarCrossref
22.
Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren.  Am J Clin Nutr. 2010;91(5):1255-126020219962PubMedGoogle ScholarCrossref
23.
Sanders KM, Stuart AL, Williamson EJ,  et al.  Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial.  JAMA. 2010;303(18):1815-182220460620PubMedGoogle ScholarCrossref
24.
Trivedi DP, Doll R, Khaw KT. Effect of 4 monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial.  BMJ. 2003;326(7387):46912609940PubMedGoogle ScholarCrossref
25.
Martineau AR. Bolus-dose vitamin D and prevention of childhood pneumonia.  Lancet. 2012;379(9824):1373-137522494825PubMedGoogle ScholarCrossref
26.
Wilbur AK, Kubatko LS, Hurtado AM, Hill KR, Stone AC. Vitamin D receptor gene polymorphisms and susceptibility M tuberculosis in native Paraguayans.  Tuberculosis (Edinb). 2007;87(4):329-33717337247PubMedGoogle ScholarCrossref
27.
Martineau AR, Timms PM, Bothamley GH,  et al.  High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial.  Lancet. 2011;377(9761):242-25021215445PubMedGoogle ScholarCrossref
28.
Committee to Review Dietary Reference Intakes for Vitamin D and Calcium.  Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press; 2011
Original Contribution
October 3, 2012

Effect of Vitamin D3 Supplementation on Upper Respiratory Tract Infections in Healthy Adults: The VIDARIS Randomized Controlled Trial

Author Affiliations

Author Affiliations: Department of Pathology, University of Otago, Christchurch (Drs Murdoch, Slow, Chambers, Jennings, and Florkowski), Canterbury Health Laboratories (Drs Murdoch, Jennings, Florkowski, and Livesey), and Department of Infectious Diseases, Christchurch Hospital (Dr Chambers), Christchurch, New Zealand; School of Population Health, University of Auckland, Auckland, New Zealand (Mr Stewart and Dr Scragg); Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand (Dr Priest); and Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (Dr Camargo).

JAMA. 2012;308(13):1333-1339. doi:10.1001/jama.2012.12505
Abstract

Context Observational studies have reported an inverse association between serum 25-hydroxyvitamin D (25-OHD) levels and incidence of upper respiratory tract infections (URTIs). However, results of clinical trials of vitamin D supplementation have been inconclusive.

Objective To determine the effect of vitamin D supplementation on incidence and severity of URTIs in healthy adults.

Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial conducted among 322 healthy adults between February 2010 and November 2011 in Christchurch, New Zealand.

Intervention Participants were randomly assigned to receive an initial dose of 200 000 IU oral vitamin D3, then 200 000 IU 1 month later, then 100 000 IU monthly (n = 161), or placebo administered in an identical dosing regimen (n = 161), for a total of 18 months.

Main Outcome Measures The primary end point was number of URTI episodes. Secondary end points were duration of URTI episodes, severity of URTI episodes, and number of days of missed work due to URTI episodes.

Results The mean baseline 25-OHD level of participants was 29 (SD, 9) ng/mL. Vitamin D supplementation resulted in an increase in serum 25-OHD levels that was maintained at greater than 48 ng/mL throughout the study. There were 593 URTI episodes in the vitamin D group and 611 in the placebo group, with no statistically significant differences in the number of URTIs per participant (mean, 3.7 per person in the vitamin D group and 3.8 per person in the placebo group; risk ratio, 0.97; 95% CI, 0.85-1.11), number of days of missed work as a result of URTIs (mean, 0.76 days in each group; risk ratio, 1.03; 95% CI, 0.81-1.30), duration of symptoms per episode (mean, 12 days in each group; risk ratio, 0.96; 95% CI, 0.73-1.25), or severity of URTI episodes. These findings remained unchanged when the analysis was repeated by season and by baseline 25-OHD levels.

Conclusion In this trial, monthly administration of 100 000 IU of vitamin D did not reduce the incidence or severity of URTIs in healthy adults.

Trial Registration anzctr.org.au Identifier: ACTRN12609000486224

×